Screening for tuberculosis in neuro-ophthalmology

References

• Salinas JL, Mindra G, Haddad MB, et al. Leveling of tuberculosis incidence — United States. Centers Dis Control Prev Morb Mortal Wkly Rep. 2013–2015 [cited 2016 July 27]. Available from: http://www.cdc.gov/mmwr/volumes/65/wr/mm6511a2.htm
   Google Scholar
• World Health Organization. Global Tuberculosis Report 2015: executive summary, 2015.
   Google Scholar
• Alvarez S, McCabe WR. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Medicine. 1984;63(1):25–55.
   PubMed Web of Science ®Google Scholar
• Gupta V, Shoughy SS, Mahajan MBBS S, et al. Clinics of ocular tuberculosis. Ocul Immunol Inflamm. 2015;23(231):14–24.
   PubMed Web of Science ®Google Scholar
• Gonzalez OY, Adams G, Teeter LD, et al. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. Int J Tuberc Lung Dis. 2003;7(12):1178–1185.
   PubMed Web of Science ®Google Scholar
• Gonzalez O, Adams G, Teeter L et al. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis: a nine year evaluation. Unpublished raw data. 2004.
   Google Scholar
• Davis EJ, Rathinam SR, Okada AA, et al. Clinical spectrum of tuberculous optic neuropathy. J Ophthalmic Inflamm Infect. 2012;2(4):183–189.
   PubMedGoogle Scholar
• La Distia Nora R, Mej VV, Ten Dam-Van Loon NH, et al. Clinical manifestations of patients with intraocular inflammation and positive QuantiFERON-TB gold in-tube test in a country nonendemic for tuberculosis. Am J Ophthalmol. 2014;157(4):754–761.
   PubMed Web of Science ®Google Scholar
• Shakarchi FI. Ocular tuberculosis: current perspectives. Clin Ophthalmol. 2015;9:2223–2227.
   PubMed Web of Science ®Google Scholar
• Patel SS, Saraiya N V, Tessler HH, et al. Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity. JAMA Ophthalmol. 2013;131(6):752–758.
   PubMed Web of Science ®Google Scholar
• Rodrigues MG, da Rocha AJ, Masruha MR, et al. Neurotuberculosis: an overview. Cent Nerv Syst Agents Med Chem. 2011;11(4):246–260.
   PubMedGoogle Scholar
• Gupta V, Gupta A, Rao NA. Intraocular tuberculosis–an update. Surv Ophthalmol. 2007;52(6):561–587.
   PubMed Web of Science ®Google Scholar
• Hong BK, Khanamiri HN, Bababeygy SR, et al. The utility of routine tuberculosis screening in county hospital patients with uveitis. Br J Ophthalmol. 2014;98(8):1091–1095.
   PubMed Web of Science ®Google Scholar
• Lou SM, Larkin KL, Winthrop K, et al. Lack of consensus in the diagnosis and treatment for ocular tuberculosis among uveitis specialists. Ocul Immunol Inflamm. 2015;23(1):25–31.
   PubMed Web of Science ®Google Scholar
• Lou SM, Montgomery PA, Larkin KL, et al. Diagnosis and treatment for ocular tuberculosis among uveitis specialists: the international perspective. Ocul Immunol Inflamm. 2015;23(1):32–39.
   PubMed Web of Science ®Google Scholar
• Tuberculosis (TB). CDC. 2016. [cited 2016 July 27]. Available from: http://www.cdc.gov/tb/default.htm
   Google Scholar
• Morinelli EN, Dugel PU, Riffenburgh R, et al. Infectious multifocal choroiditis in patients with acquired immune deficiency syndrome. Ophthalmology. 1993;100(7):1014–1021.
   PubMed Web of Science ®Google Scholar
• Sudharshan S, Kaleemunnisha S, Banu AA, et al. Ocular lesions in 1,000 consecutive HIV-positive patients in India: a long-term study. J Ophthalmic Inflamm Infect. 2013;3(1):2.
   PubMedGoogle Scholar
• Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for latent tuberculosis infection in adults. JAMA. 2016;316(9):962.
   PubMed Web of Science ®Google Scholar
• Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection — United States. 2010 Methods for Updating IGRA Guidelines. 2010;59:1–25. [cited 2016 July 27]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm
   Google Scholar
• Nienhaus A, Schablon A, Costa JT, et al. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res. 2011;11(1):247.
   PubMed Web of Science ®Google Scholar
• Hardy AB, Varma R, Collyns T, et al. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax. 2010;65(2):178–180.
   PubMed Web of Science ®Google Scholar
• Ang M, Vasconcelos-Santos DV, Sharma K, et al. Diagnosis of ocular tuberculosis. Ocul Immunol Inflamm. 2016;3948:1–9.
   Google Scholar
• Ang M, Nguyen HV, Kiew SY, et al. Cost-effectiveness of alternative strategies for interferon-γ release assays and tuberculin skin test in tuberculous uveitis. Br J Ophthalmol. 2015;99(7):984–989.
   PubMed Web of Science ®Google Scholar
• Tagmouti S, Slater M, Benedetti A, et al. Reproducibility of Interferon Gamma (IFN-γ) release assays. A systematic review. Ann Am Thorac Soc. 2014;11(8):1267–1276.
   PubMedGoogle Scholar
• Banaei N, Gaur RL, Pai M. Interferon gamma release assays for latent tuberculosis: what are the sources of variability? J Clin Microbiol. 2016;54(4):845–850.
   PubMedGoogle Scholar
• Lee C, Frcs RA, Pavesio C, et al. A clinical conundrum ocular tuberculosis — a clinical conundrum. Ocul Immun Inflamm. 2016;24(2):237–242.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Tuberculin skin testing. Cent Dis Control. 2011;8. Available from: http://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm
   Google Scholar
• Guglielmetti L, Conti M, Cazzadori A, et al. Diagnostic sensitivity of QuantiFERON-TB gold in-tube and tuberculin skin test in active tuberculosis: influence of immunocompromission and radiological extent of disease. Infez Med. 2012;20(1):16–24.
   PubMedGoogle Scholar
• Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis. 1993;17(6):968–975.
   PubMed Web of Science ®Google Scholar
• Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099–1104.
   PubMed Web of Science ®Google Scholar
• Vinton P, Mihrshahi S, Johnson P, et al. Comparison of QuantiFERON-TB gold in-tube test and tuberculin skin test for identification of latent Mycobacterium tuberculosis infection in healthcare staff and association between positive test results and known risk factors for infection. Infect Control Hosp Epidemiol. 2009;30:215–221.
   PubMed Web of Science ®Google Scholar
• Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005;293(22):2756–2761.
   PubMed Web of Science ®Google Scholar
• QuantiFERON-TB Gold What is QuantiFERON-TB Gold? Cellestis, QIAGEN. 2016. [cited 2016 July 27]. Available from: http://www.quantiferon.com/irm/content/quantiferon-tb-gold1.aspx?RID=300
   Google Scholar
• Daley CL, Reves RR, Beard MA, et al. A summary of meeting proceedings on addressing variability around the cut point in serial interferon-γ release assay testing. Infect Control Hosp Epidemiol. 2013;34(6):625–630.
   PubMed Web of Science ®Google Scholar
• Mancuso JD, Mazurek GH, Tribble D, et al. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med. 2012;185(4):427–434.
   PubMed Web of Science ®Google Scholar
• Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45–55.
   PubMed Web of Science ®Google Scholar
• Ndzi EN, Nkenfou CN, Gwom LC, et al. The pros and cons of the QuantiFERON test for the diagnosis of tuberculosis, prediction of disease progression, and treatment monitoring. Int J Mycobacteriology. 2016;5(2):177–184.
   PubMed Web of Science ®Google Scholar
• Anwar A, Hamdan A-J, Salim B, et al. Diagnostic utility of QuantiFERON-TB Gold (QFT-G) in active pulmonary tuberculosis. J Glob Infect Dis. 2015;7(3):108–112.
   PubMed Web of Science ®Google Scholar
• Pai M, Denkinger CM, Kik SVEA. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3–20.
   PubMed Web of Science ®Google Scholar
• Ringshausen FC, Nienhaus A, Costa JT, et al. Within-subject variability of Mycobacterium tuberculosis-specific gamma interferon responses in German health care workers. Clin Vaccine Immunol. 2011;18(7):1176–1182.
   PubMed Web of Science ®Google Scholar
• Fong KS, Tomford JW, Teixeira L, et al. Challenges of interferon-γ release assay conversions in serial testing of health-care workers in a TB control program. Chest. 2012;142(1):55–62.
   PubMed Web of Science ®Google Scholar
• Detjen AK, Loebenberg L, Grewal HMS, et al. Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol. 2009;16(8):1170–1175.
   PubMed Web of Science ®Google Scholar
• Zwerling A, van den Hof S, Scholten J, et al. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax. 2012;67(1):62–70.
   PubMed Web of Science ®Google Scholar
• QuantiFEROn-TB Gold (QFT) ELISA Package Insert, Chadstone, Australia: Cellestis, a QIAGEN Company; 2013. Available from: http://www.quantiferon.com/irm/content/PI/QFT/2PK/UK.pdf
   Google Scholar
• Metcalfe JZ, Cattamanchi A, McCulloch CE, et al. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med. 2013;187(2):206–211.
   PubMed Web of Science ®Google Scholar
• Little L, Rigi M, Suleiman A, et al. QuantiFERON-TB gold in-tube assays in neuro-ophthalmology. J Neuro-Ophthalmology 2016. [Epub ahead of print]
   Google Scholar
• Gamsky TE, Lum T, Hung-Fan M, et al. Cumulative False positive QuantiFERON-TB interferon-gamma release assay results. Ann Am Thorac Soc. 2016;13(5):660–665.
   PubMed Web of Science ®Google Scholar
• Slater ML, Welland G, Pai M, et al. Challenges with QuantiFERON-TB gold assay for large-scale, routine screening of U.S. healthcare workers. Am J Respir Crit Care Med. 2013;188(8):1005–1010.
   PubMed Web of Science ®Google Scholar
• Dorman SE, Belknap R, Graviss EA, et al. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189(1):77–87.
   PubMed Web of Science ®Google Scholar
• Zwerling A, Benedetti A, Cojocariu M, et al. Repeat IGRA testing in Canadian health workers: conversions or unexplained variability? PLoS One. 2013;8(1):1–10.
   Web of Science ®Google Scholar
• Thanassi W, Noda A, Hernandez B et al. Delineating a retesting zone using receiver operating characteristic analysis on serial QuantiFERON tuberculosis test results in US healthcare workers. 2012:291294. [cited 2016 July 27]. Available from: http://www.hindawi.com/journals/pm/2012/291294/.
   Google Scholar
• Person AK, Pettit AC, Sterling TR. Diagnosis and treatment of latent tuberculosis infection: an update. Curr Respir Care Rep. 2013;2(4):199–207.
   PubMedGoogle Scholar
• Yan L, Xiao H, Han M, et al. Diagnostic value of T-SPOT.TB interferon-γ release assays for active tuberculosis. Exp Ther Med. 2015;10(1):345–351.
   PubMed Web of Science ®Google Scholar
• Zhou XX, Liu YL, Zhai K, et al. Body fluid interferon-γ release assay for diagnosis of extrapulmonary tuberculosis in adults: a systematic review and meta-analysis. Sci Rep. 2015;5:15284.
   PubMed Web of Science ®Google Scholar
• Kim SH, Cho OH, Park SJ, et al. Rapid diagnosis of tuberculous meningitis by T cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Infect Dis. 2010;50(10):1349–1358.
   PubMed Web of Science ®Google Scholar
• Floyd K, Falzon D, Getahun H, et al. Use of high burden country lists for TB by WHO in the post-2015 era. World Heal Organ. 2015 [cited 2016 Aug 7]; Available from: http://www.who.int/tb/publications/global_report/high_tb_burdencountrylists2016-2020.pdf
   Google Scholar
• Rosenbaum JT, Wernick R. The utility of routine screening of patients with uveitis for systemic lupus erythematosus or tuberculosis. A Bayesian analysis. Arch Ophthalmol. 1990;108(9):1291–1293.
   PubMedGoogle Scholar
• Latent Tuberculosis Infection: A Guide for Primary Health Care Providers. CDC 2013. [cited 2016 July 27]. Available from: http://www.cdc.gov/tb/publications/ltbi/treatment.htm
   Google Scholar
• Use of tuberculosis release assays (IGRAs) in low- and middle- income countries. World Heal Organ 2011. [cited 2016 Aug 7]. Available from: http://www.who.int/tb/publications/tb-igraexpertmeeting-report/en/
   Google Scholar
• Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest. 2012;142(1):63–75.
   PubMed Web of Science ®Google Scholar
• Feske ML, Teeter LD, Musser JM, et al. Including the third dimension : a spatial analysis of TB cases in Houston Harris County. Tuberculosis. 2011;91:S24–S33.
   PubMed Web of Science ®Google Scholar
• QuantiFERON-TB Gold Plus (QFT-Plus) ELISA Package Insert. QIAGEN 2015. Available from: http://www.quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf
   Google Scholar